Four Targeted Biologics Are Transforming Severe Eczema Treatment
A comprehensive review reveals how dupilumab, tralokinumab, lebrikizumab, and nemolizumab are reshaping care for moderate-to-severe atopic dermatitis.
Summary
Atopic dermatitis affects up to 15% of children and 8% of adults worldwide, with roughly 5–20% experiencing severe disease requiring systemic treatment. Before 2017, only broad immunosuppressants were available, carrying significant toxicity. This review synthesizes real-world and clinical trial data on four approved biologics: dupilumab (blocks IL-4/IL-13 signaling), tralokinumab and lebrikizumab (selectively target IL-13), and nemolizumab (targets IL-31 to reduce itch). All four demonstrate meaningful improvements in skin scores, itch, and quality of life across age groups, with favorable safety profiles compared to older systemic therapies. The review also previews emerging biologics—including OX40/OX40L-targeting agents—currently in phase 3 trials.
Detailed Summary
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with profound effects on quality of life, work productivity, and mental health. The majority of patients manage with topical treatments, but 5–20% require systemic therapy. Prior to 2017, this meant broad immunosuppressants with significant cumulative toxicity and limited long-term effectiveness—a major unmet need in dermatology.
This narrative review, authored by leading AD specialists across Europe and the US, synthesizes primarily real-world evidence (RWE) alongside randomized controlled trial (RCT) data to evaluate four approved type 2 (T2) inflammation-targeting biologics. The authors prioritized peer-reviewed real-world studies published within approximately two years, supplementing with RCTs where RWE was absent. Dupilumab—the first approved biologic (2017 in the US, 2019 in Europe)—binds the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling. Tralokinumab and lebrikizumab each bind distinct epitopes of IL-13, preventing receptor interaction. Nemolizumab targets the IL-31 receptor alpha, directly addressing the neuroinflammatory itch pathway.
Key effectiveness outcomes were organized using the Treat-to-Target framework: EASI-75 or EASI ≤7, IGA 0/1, NRS pruritus ≥4-point improvement or ≤4, and DLQI ≤5 or ≥4-point improvement. Across both 16-week and 52-week timepoints, all three T2 biologics with available data (dupilumab, tralokinumab; lebrikizumab only in RCTs) showed clinically meaningful improvements across skin severity, itch, and quality-of-life measures, with effectiveness appearing largely independent of age. Real-world studies specifically confirm that dupilumab maintains its effectiveness over multi-year follow-up and across pediatric, adolescent, and adult populations.
Safety profiles for all four biologics are generally favorable. The most common side effects unique to the IL-4/IL-13 pathway agents include conjunctivitis (particularly with dupilumab) and injection-site reactions. Nemolizumab's safety profile centers on injection-site reactions and potential transient worsening of AD in some patients. No increased risk of serious infections, malignancy, or cardiovascular events has emerged in long-term registries. The review provides practical clinical guidance on managing the most common adverse effects, including ophthalmologic referral pathways for persistent dupilumab-associated conjunctivitis.
Looking ahead, the review highlights emerging biologics in phase 3 trials targeting the OX40–OX40L axis—rocatinlimab (anti-OX40 receptor) and amlitelimab (anti-OX40L)—which modulate T-cell activation and memory, potentially offering durable disease modification. These agents represent a conceptually distinct mechanism from current cytokine-blocking strategies and could expand therapeutic options, particularly for patients with inadequate responses to existing biologics.
Key Findings
- Dupilumab, tralokinumab, lebrikizumab, and nemolizumab all demonstrate significant, clinically meaningful improvements in skin severity and itch vs. older systemic therapies.
- Real-world data confirm dupilumab's effectiveness is maintained long-term and across all age groups, from children to older adults.
- Safety profiles across all four biologics are favorable; conjunctivitis is the most notable dupilumab-specific adverse effect requiring monitoring.
- OX40/OX40L-targeting biologics in phase 3 trials may offer a distinct, potentially disease-modifying mechanism for AD.
- Nemolizumab uniquely targets the IL-31 neuroinflammatory itch pathway, addressing pruritus more directly than IL-4/IL-13 blockers.
Methodology
This is a non-systematic narrative review; sources were selected based on relevance and scientific credibility, prioritizing peer-reviewed real-world studies published within approximately two years. RCT data were used to supplement where real-world evidence was lacking. No formal search strategy or meta-analytic pooling was performed.
Study Limitations
As a non-systematic narrative review, selection bias in included studies is possible and no pooled effect sizes are reported. Real-world data for tralokinumab, lebrikizumab, and nemolizumab remain limited compared to the extensive dupilumab evidence base. Head-to-head comparative effectiveness trials between the four approved biologics are largely absent.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.